Physician profile
Ibrahim Helmy
NPI 1598795247
$4,971.32
in general payments reported to CMS, 2019-2025
27 companies · $932 in 2025
The $932 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $289 · 2021: $529 · 2022: $624 · 2023: $1,364 · 2024: $798 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,013 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,013.46 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,072.41 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $493.72 | 2022-2025 | |
| Pfizer INC. | $468.08 | 2019-2025 | |
| Amgen INC. | $439.83 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.53 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $329.24 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $294.24 | 2022-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $190.89 | 2019-2025 | Camzyos, Eliquis |
| Astellas Pharma US INC | $176.23 | 2020-2023 | |
| Abbott Laboratories | $150.81 | 2021-2024 | Mitraclip |
| Lexicon Pharmaceuticals, INC. | $142.17 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $141.22 | 2020-2025 | Brilinta, Wainua, Farxiga |
| Scpharmaceuticals INC. | $114.43 | 2024 | |
| Bridgebio Pharma, INC. | $102.08 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $98.18 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $60.85 | 2023 | Optimizer |
| Boston Scientific Corporation | $53.15 | 2022-2023 | Watchman Access System |
| Kestra Medical Technology Services, INC. | $40.95 | 2025 | Assure Wcd |
| Akcea Therapeutics, INC. | $29.24 | 2019 | |
| Chiesi USA, INC. | $27.98 | 2025 | Juxtapid |
| Heartflow, INC. | $23.88 | 2025 | |
| Sanofi-Aventis U.S. LLC | $22.99 | 2019 | |
| Esperion Therapeutics, INC. | $22.97 | 2025 | Nexletol |
| Coala Life INC | $19.26 | 2020 | |
| Glaxosmithkline, LLC. | $18.71 | 2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $18.28 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Helmy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.